Journal of Neurology & Neurophysiology

ISSN - 2155-9562

Francois Curtin

Francois Curtin
GeNeuro SA Chemin des Aulx 18 CH-1228 Plan-les-Ouates/Geneva,

  • Short Communication
    Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?
    Author(s): Francois CurtinFrancois Curtin

    End of December 2013, alemtuzumab, a monoclonal antibody for multiple sclerosis (MS) with an immunomodulator action targeting CD52 receptors and inducing decrease counts of lymphocytes B and T was rejected by the Food and Drug Administration, as the registration dossier had not shown convincing evidence that the benefit of the drug would overreach its safety risks. The question is in fact more global as immunomodulators constitute the majority of the newly registered drugs and drugs in clinical development for MS. The knowledge accumulated by the time these drugs are registered does not suffice to ascertain their safety profile. This is preoccupying as these treatments are intended to be administered to young patients who need to be treated for decades. Cumulative risks over years with such treatments are at the moment unknown but are c.. View More»

    DOI: 10.4172/2155-9562.1000197

    Abstract PDF

Relevant Topics